36 nanotimes Companies Facts
S tarpharma Holdings Ltd (ASX:SPL, OTCQX: SPHRY) reported excellent progress in the recruitment for its pivotal Phase 3 trials for VivaGel(R) as a treatment for bacterial vaginosis (BV). Two concurrent Phase 3 trials are underway and recruitment for these trials, which commenced in late March 2012, has recently passed the halfway mark with 60% of patients already enrolled. One of the trials has already exceeded 80% enrolment. The Phase 3 treatment trials are taking place across more than 30 international sites, primarily in the United States. Following the completion of the Phase 3 trials Starpharma expects to prepare and submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in parallel with engaging in licensing negotiations. The FDA has already provided formal agreement as part of a Special Protocol Assessment (SPA) declaring that the phase 3 trials' design, clinical endpoints and statistical analyses are acceptable for FDA approval once completed. "We are extremely pleased with the rate of enrolment for the pivotal Phase 3 trials underway. We are already approaching two thirds enrolment in less than three months, which means we are well on track to complete and report the trials in 2012 as indicated," said Dr Jackie Fairley, Chief Executive Officer of Starpharma.
The market for topical treatments of BV is estimated at US$300-$350 million. Moreover, Starpharma Holdings reported that recruit-ment is now 100% complete for its Phase 2 clinical trial to investigate the ability of VivaGel(R) to prevent the recurrence of BV, and also for the first of two pivotal Phase 3 studies of VivaGel(R) for the treatment of BV. The primary objective of the study is to determine the efficacy of two strengths of VivaGel(R) (containing 1% or 3% SPL7013) compared with a placebo gel in preventing recurrence of BV. The product is used every second day over a period of 16 weeks. Starpharma also provided an update on the developments within its substantial drug delivery program. Starpharma’s program to enhance the blockbuster cancer drug docetaxel is advancing rapidly and plans are underway for clinical trials to commence in 2013. Starpharma has also demonstrated its dendrimer technology’s applicability to hormones such as insulin, and antibodies, further diversifying drug delivery product potential into these high-growth segments of the market. In addition, Starpharma continues to expand its partnered delivery programs with major pharmaceutical companies’ proprietary drugs.
http://www.starpharma.com
Tegal Corporation (NASDAQ:TGAL) announced financial results for the fourth quarter and fiscal year 2012, which ended March 31, 2012. The Company’s net (loss) per share decreased to ($0.85) for the year from a comparable ($1.85) from the prior fiscal year. The Company ended the fiscal year with $7.8 million in cash, an increase over the prior year of approximately $0.2 million. This balance reflects the use of cash for the investment in NanoVibronix and proceeds of the IP asset sale. Tegal and its portfolio companies achieved numerous milestones in Fiscal Year 2012. Tegal’s two portfolio companies are Sequel Power, a private company dedicated to the development and operation of large scale photovoltaic (PV)-based solar utility projects. Tegal made a $300,000 strategic investment in Nano-Vibronix Inc., a medical device company focused on creating products utilizing its proprietary low-intensity surface acoustic wave (SAW) technology. The company‘s unique, patented approach enables the transmission of low-frequency, low-intensity ultrasound waves through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets. Moreover, Tegal has signed a definitive agreement to acquire CollabRx, Inc., a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine.
http://www.tegal.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89